SCHEMBL1787489

SCHEMBL1787489

COc1cc(Cl)c(C(N)=O)cc1N1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 3/20 0.51
MAPK8 P45983 2/20 0.51
MAPK9 P45984 2/20 0.51
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 2/20 0.47
NPC1 O15118 1/20 0.46
NFKB1 P19838 1/20 0.46
RAB9A P51151 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
HCAR1 Q9BXC0 3/20 0.46
HCAR2 Q8TDS4 1/20 0.46
MAPK1 P28482 1/20 0.45
TSHR P16473 2/20 0.44
LMNA P02545 1/20 0.43
POLB P06746 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789465 0.88 SMN1; SMN2 (0.48) MAPTSMN1; SMN2ALDH1A1NPC1NFKB1
SCHEMBL1785833 0.87 MAPT (0.50) MAPTSMN1; SMN2ALDH1A1NPC1NFKB1
SCHEMBL12316379 0.84 MAPT (0.47) MAPK10MAPK8MAPK9MAPTSMN1; SMN2
SCHEMBL1785947 0.83 MAPT (0.51) MAPTSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL3839691 0.76 ALDH1A1 (0.54) MAPK10MAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL17779277 0.75 KDM4E (0.50) SMN1; SMN2ALDH1A1TSHRPOLBKDM4E
SCHEMBL12316373 0.75 HTT (0.49) MAPTSMN1; SMN2ALDH1A1NPC1NFKB1
SCHEMBL11064644 0.75 MAPT (0.49) MAPTSMN1; SMN2ALDH1A1NPC1NFKB1
SCHEMBL1790337 0.74 ALDH1A1 (0.49) MAPTSMN1; SMN2ALDH1A1NPC1NFKB1
SCHEMBL12316372 0.74 GAA (0.52) MAPTSMN1; SMN2ALDH1A1NPC1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2013-08-08 US disclosed
EP-2607357-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS Astrazeneca AB (SE) 2013-06-26 EP disclosed
US-20120115845-A1 THERAPEUTIC AGENTS ALLEN JACK MCQUEEN (GB) 2012-05-10 US disclosed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 US disclosed
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 EP disclosed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 US disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R MAPK10 1224/4885MAPK8 2158/4885MAPK9 2349/4885
US-20120115845-A1 THERAPEUTIC AGENTS GPR119, MC2R, MC4R MAPK10 561/4885MAPK8 1539/4885MAPK9 2361/4885
US-20090186870-A1 Therapeutic Agents - 802 GPR119, SLC5A2, MC2R MAPK10 275/4885MAPK8 1159/4885MAPK9 2514/4885
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R MAPK10 1224/4885MAPK8 2158/4885MAPK9 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.